Cambridge id 5347486

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Cambridge id 5347486
• 英文别名: 1-(4-nitrophenyl)sulfonyl-4-[(E)-3-phenylprop-2-enyl]piperazine
• 化学式: C19H21N3O4S
• 分子量: 387.5
• InChiKey: FJKNPJWTEZBBKX-QPJJXVBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  94.8
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• Method of treating fibrosis
  申请人：BCN Biosciences L.L.C.

  公开号：US11229635B2

  公开（公告）日：2022-01-25

  The present disclosure is directed to method of treatment for treating or ameliorating various conditions pertaining such as bone marrow recovery (or blood cell production), fibrosis, inflammatory diseases, inhibition of cancer cell growth, propagation or malignancy, thrombocytopenia, wound healing, and conditions related to stem cells by the administration of BCN057, 512, or an analog thereof.

  本公开涉及通过施用BCN057、512或其类似物治疗或改善各种相关病症的方法，如骨髓恢复（或血细胞生成）、纤维化、炎症性疾病、抑制癌细胞生长、繁殖或恶性肿瘤、血小板减少、伤口愈合以及与干细胞相关的病症。
• Methods of treating radiation induced gastrointestinal syndrome (RIGS) and related disease states using compound 512
  申请人：BCN Biosciences L.L.C.

  公开号：US11534437B2

  公开（公告）日：2022-12-27

  The present disclosure is directed to method of treatment for treating or ameliorating various conditions caused by radiation exposure such as RIGS, enteritis, mucositis, e.g., oral mucositis, and proctitis by the administration of compound 512, or an analog thereof.

  本公开涉及通过施用化合物 512 或其类似物来治疗或改善由辐射照射引起的各种病症（如 RIGS、肠炎、粘膜炎（如口腔粘膜炎）和直肠炎）的治疗方法。
• RADIOMITIGATING PHARMACEUTICAL FORMULATIONS
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20160090369A1

  公开（公告）日：2016-03-31

  The present disclosure relates to compounds of Formula (I) and (II), compositions containing the compounds (alone or in combination with other agents), and their use to prevent, mitigate or treat a) damage induced by ionizing radiation, b) inflammation or c) cancer.
• METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING BCN057 OR BCN512
  申请人：BCN Biosciences L.L.C.

  公开号：US20180104233A1

  公开（公告）日：2018-04-19

  The present disclosure is directed to method of treatment for treating or ameliorating various conditions pertaining such as bone marrow recovery (or blood cell production), fibrosis, inflammatory diseases, inhibition of cancer cell growth, propagation or malignancy, thrombocytopenia, wound healing, and conditions related to stem cells by the administration of BCN057, 512, or an analog thereof.
• METHODS OF TREATING RADIATION INDUCED GASTROINTESTINAL SYNDROME (RIGS) AND RELATED DISEASE STATES USING COMPOUND 512
  申请人：BCN Biosciences L.L.C.

  公开号：US20190046524A1

  公开（公告）日：2019-02-14

  The present disclosure is directed to method of treatment for treating or ameliorating various conditions caused by radiation exposure such as RIGS, enteritis, mucositis, e.g., oral mucositis, and proctitis by the administration of compound 512, or an analog thereof.